Tumor Biology

, Volume 36, Issue 5, pp 3557–3564 | Cite as

AURKA is a predictor of chemotherapy response and prognosis for patients with advanced oral squamous cell carcinoma

Research Article


Increasing evidence proposes the benefits of cisplatin-based chemotherapy in a subpopulation of patients with oral squamous cell carcinoma (OSCC), yet reliable indicators for this subpopulation are poorly explored. AURKA, also known as aurora kinase A, playing important functions in cell mitosis and making cells resistant to cisplatin through dysregulation of DNA damage repair networks, has been reported to be upregulated in OSCC, making AURKA a promising indicator. In this study, we recruited 78 patients with advanced OSCC to examine the expression of AURKA and the correlation with chemotherapy response and clinical outcomes. We found that AURKA was strongly expressed in 31 (39.74 %) of the 78 advanced OSCC samples and its expression was significantly associated with cisplatin resistance (P = 0.023), clinical recurrence (P = 0.021), and 5-year survival (P = 0.019). Chemotherapy increased AURKA expression in post-chemotherapy samples, yet with no significance (P = 0.101). Multivariate Cox proportional hazards regression model analysis demonstrated that lymph node samples with positive, strong AURKA staining, and poor chemotherapy response were independently associated with the 5-year survival and disease-free survival. Inhibiting AURKA expression in OSCC cell lines remarkably increased their sensitivity to cisplatin treatment by 2.5-fold difference. Our results imply that the overexpression of AURKA in advanced OSCC not only plays a role in the disease course but also shows an involvement in cisplatin treatment response. AURKA level may be a valuable predictor for patients with advanced OSCC, with downregulation of AURKA being a promising adjuvant therapy in this patient population.


Aurora kinase A Oral squamous cell carcinoma Chemotherapy Indicator Prognosis 



This study was partly supported by the Natural Science Foundation Project of CQ CSTC (cstc2012jjA10039), Chongqing Municipal Health Bureau (Grant No. 2012-2-049,2011-2-013), and Chongqing Municipal Commission of Education (KJ130318).

Conflicts of interest


Supplementary material

13277_2014_2992_MOESM1_ESM.doc (3 mb)
Supplemental Fig. 1 (DOC 3118 kb)
13277_2014_2992_MOESM2_ESM.doc (28 kb)
Supplemental Table 1 (DOC 28 kb)


  1. 1.
    Hauswald H, Simon C, Hecht S, Debus J, Lindel K. Long-term outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol. 2011;6:70.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011;117:4671–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang R, Wang JH, Chu XY, Geng HC, Chen LB. Expression of stk15 mRNA in hepatocellular carcinoma and its prognostic significance. Clin Biochem. 2009;42:641–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, et al. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia. 2009;11:418–25.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kiyose S, Nagura K, Tao H, Igarashi H, Yamada H, Goto M, et al. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int. 2012;62:477–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Pan JY, Ajani JA, Gu J, Gong Y, Quin A, Hung M, et al. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer. 2012;118:4346–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, et al. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy. Int J Oncol. 2007;31:793–802.PubMedGoogle Scholar
  8. 8.
    Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Yang H, He L, Kruk P, Nicosia SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119:2304–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, et al. Aurora kinase-a inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell. 2012;21:196–211.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zeng JY, Sharma S, Zhou YQ, Yao HP, Hu X, Zhang R, et al. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther. 2014;13:37–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Yao R, Zheng J, Zheng W, Gong Y, Liu W, Xing R. Vx680 suppresses the growth of Hepg2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett. 2014;7:121–4.PubMedGoogle Scholar
  13. 13.
    Ke CS, Liu HS, Yen CH, Huang GC, Cheng HC, Huang CY et al. Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. J Nutritional Biochem 2014Google Scholar
  14. 14.
    Lee YR, Wu WC, Ji WT, Chen JY, Cheng YP, Chiang MK, et al. Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J Biomed Sci. 2012;19:9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tanaka H, Nakashiro K, Iwamoto K, Tokuzen N, Fujita Y, Shirakawa R, et al. Targeting aurora kinase a suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo. Oral Oncol. 2013;49:551–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, et al. Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncol. 2008;44:639–45.CrossRefPubMedGoogle Scholar
  17. 17.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefGoogle Scholar
  18. 18.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Radiation Therapy Oncology G, Intergroup USA: Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719–25.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhong LP, Zhang CP, Ren GX, Guo W, William Jr WN, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Sun H, Wang Y, Wang Z, Meng J, Qi Z, Yang G. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. Biochim Biophys Acta. 1843;2014:934–44.Google Scholar
  22. 22.
    Sehdev V, Katsha A, Arras J, Peng D, Soutto M, Ecsedy J, et al. HDM2 regulation by AURKA promotes cell survival in gastric cancer. Clin Cancer Res. 2014;20:76–86.CrossRefPubMedGoogle Scholar
  23. 23.
    Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, et al. The aurora kinase a inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Therapeut. 2012;11:763–74.CrossRefGoogle Scholar
  24. 24.
    Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, Yang CZ, et al. XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS One. 2012;7:e31601.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Moreno-Galindo C, Hermsen M, Garcia-Pedrero JM, Fresno MF, Suarez C, Rodrigo JP. P27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol. 2014;50:128–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J, et al. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One. 2011;6:e26399.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Oral and Maxillofacial SurgeryThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations